FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1551340235> ?p ?o ?g. }

• W1551340235 endingPage "203" @default.
• W1551340235 startingPage "197" @default.
• W1551340235 abstract "Dibromomannitol (DBM) is a new agent for the treatment of chronic granulocytic leukemia. A propsective evaluation of the drug was undertaken in a randomized comparison with busulfan. Forty previously untreated, Philadelphia chromosome-positive cases were treated, with 20 patients in each treatment group. The protocol provided for continuous maintenance therapy after remission induction, with a crossover to the opposite drug in patients who became refractory to the primary agent but are without evidence of blastic tranformation. There were 14 remissions in the DBM group and 15 in those treated with busulfan. The rate of decrease of the elevated leukocyte count was more rapid with DBM, but prolonged disease control off treatment occurred in only three of 14 cases as opposed to nine of fifteen busulfan-treated patients who required a median delay of 12 mo before maintenance could be initiated. Hypoplasia occurred in one DBM patient and two busulfan cases. Following recovery, crossover to the opposite drug in two cases again resulted in hypopllasia. Increased skin pigmentation, amenorrhea, pulmonary fibrosis, and cytologic dysplasia, commonly associated with busulfan adminstration, were also noted with DBM. The median duration of disease control with busulfan was 34 mo and 26 mo with DBM. There was no signigicant difference in the incidence of blastic transformation, and median survival for both groups was 44 mo. DBM appears to be as effective as busulfan in the treatment of the chronic phase of CGL but with a more predictable myelosuppressive action. The principal advantage of busulfan over DBM is the fact that more than half the busulfan-treated patients experienced prolonged disease control off treatment." @default.
• W1551340235 created "2016-06-24" @default.
• W1551340235 creator A5061110344 @default.
• W1551340235 creator A5066366437 @default.
• W1551340235 creator A5077084708 @default.
• W1551340235 creator A5077350164 @default.
• W1551340235 date "1975-02-01" @default.
• W1551340235 modified "2023-09-30" @default.
• W1551340235 title "Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan" @default.
• W1551340235 cites W1981677840 @default.
• W1551340235 cites W1984535202 @default.
• W1551340235 cites W2065657368 @default.
• W1551340235 cites W2071732759 @default.
• W1551340235 cites W2080084081 @default.
• W1551340235 cites W2220969391 @default.
• W1551340235 cites W2288709380 @default.
• W1551340235 cites W2296580809 @default.
• W1551340235 cites W2400203925 @default.
• W1551340235 cites W2403905451 @default.
• W1551340235 cites W2417534787 @default.
• W1551340235 cites W2418265820 @default.
• W1551340235 cites W2443097216 @default.
• W1551340235 doi "https://doi.org/10.1182/blood.v45.2.197.bloodjournal452197" @default.
• W1551340235 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1054609" @default.
• W1551340235 hasPublicationYear "1975" @default.
• W1551340235 type Work @default.
• W1551340235 sameAs 1551340235 @default.
• W1551340235 citedByCount "11" @default.
• W1551340235 countsByYear W15513402352013 @default.
• W1551340235 crossrefType "journal-article" @default.
• W1551340235 hasAuthorship W1551340235A5061110344 @default.
• W1551340235 hasAuthorship W1551340235A5066366437 @default.
• W1551340235 hasAuthorship W1551340235A5077084708 @default.
• W1551340235 hasAuthorship W1551340235A5077350164 @default.
• W1551340235 hasBestOaLocation W15513402351 @default.
• W1551340235 hasConcept C126322002 @default.
• W1551340235 hasConcept C141071460 @default.
• W1551340235 hasConcept C2776694085 @default.
• W1551340235 hasConcept C2776755627 @default.
• W1551340235 hasConcept C2780611847 @default.
• W1551340235 hasConcept C71924100 @default.
• W1551340235 hasConcept C90924648 @default.
• W1551340235 hasConceptScore W1551340235C126322002 @default.
• W1551340235 hasConceptScore W1551340235C141071460 @default.
• W1551340235 hasConceptScore W1551340235C2776694085 @default.
• W1551340235 hasConceptScore W1551340235C2776755627 @default.
• W1551340235 hasConceptScore W1551340235C2780611847 @default.
• W1551340235 hasConceptScore W1551340235C71924100 @default.
• W1551340235 hasConceptScore W1551340235C90924648 @default.
• W1551340235 hasIssue "2" @default.
• W1551340235 hasLocation W15513402351 @default.
• W1551340235 hasOpenAccess W1551340235 @default.
• W1551340235 hasPrimaryLocation W15513402351 @default.
• W1551340235 hasRelatedWork W2002120878 @default.
• W1551340235 hasRelatedWork W2003938723 @default.
• W1551340235 hasRelatedWork W2047967234 @default.
• W1551340235 hasRelatedWork W2118496982 @default.
• W1551340235 hasRelatedWork W2364998975 @default.
• W1551340235 hasRelatedWork W2369162477 @default.
• W1551340235 hasRelatedWork W2439875401 @default.
• W1551340235 hasRelatedWork W4238867864 @default.
• W1551340235 hasRelatedWork W2519357708 @default.
• W1551340235 hasRelatedWork W2525756941 @default.
• W1551340235 hasVolume "45" @default.
• W1551340235 isParatext "false" @default.
• W1551340235 isRetracted "false" @default.
• W1551340235 magId "1551340235" @default.
• W1551340235 workType "article" @default.